GW Pharma (GWPH) Posts Q3 Loss as Revenues Beat

GW Pharma (NASDAQ: GWPH) reported Q3 EPS of ($0.39) per per share, or $4.64 per ADS, versus the analyst estimate of ($1.51). Revenue for the quarter came in at $3.14 million versus the consensus estimate of $2.57 million.

“I am pleased to report the NDA submission process for Epidiolex is now underway with the final sections of the submission expected to be completed in October. With a clear view now towards our anticipated approval, we are making excellent progress with preparations to ensure a highly successful launch in 2018,” stated Justin Gover, GW’s Chief Executive Officer. “Following the recent publication of our first Phase 3 trial in The New England Journal of Medicine, we look forward to additional Epidiolex data publications and presentations in the second half of the year. In addition to Epidiolex, we continue to keep focus on our growing and innovative cannabinoid pipeline where we have advanced a number of additional exciting clinical programs.”

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance